CRISPR Therapeutics AG — Director's Dealing 2022

Oct 12, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2022-10-07

Reporting Person: Morrow Phuong Khanh (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-07	Stock Option (Right to Buy)	$61.65	A	9380	Acquired	2032-10-07	Common Shares (9380)	Direct

Footnotes

F1: This option was granted on October 7, 2022 with respect to 9,380 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 7, 2022.